Movement Alert|CRISPR Therapeutics AG Intraday Decline 5.01%, valuation debate and recent earnings miss weigh on shares

Market Focus
11/12

On November 12, CRISPR Therapeutics AG fell 5.01% in Regular Trading, trading at $43.44 per share, with turnover of $18.8672 million.

The most recent market update tied the weakness to renewed valuation debate after recent clinical disclosures, alongside pressure from the company’s latest quarterly results. CRISPR Therapeutics AG previously reported September-quarter EPS of $1.15 loss, wider than the $0.98 loss expected by analysts, although revenue of $12.669 million exceeded estimates.

Recent pipeline news was constructive but did not prevent the selloff. On November 9, the company presented Phase 1b data for CTX310 showing mean reductions from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides after a single-course treatment. Earlier, autoimmune data for zugo-cel also showed encouraging early responses. Even so, the latest market interpretation emphasized continuing losses and uncertainty around commercialization timing.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10